Skip to main content
Sacubitril/Valsartan and Frailty in HFpEF in PARAGON-HF | ESC Congress 2022
Jawad H. Butt, MD, talks about sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction; a post-hoc analysis from the PARAGON-HF trial.
Natural History of MYH7-related Dilated Cardiomyopathy | ESC Congress 2022
Fernando de Frutos, MD, summarizes his paper on the natural history of MYH7-related dilated cardiomyopathy.
LBCT Dapagliflozin and Atrial Fibrillation in HFpEF in DELIVER | ESC Congress 2022
Jawad H. Butt, MD, talks about the efficacy and safety of atrial fibrillation in patients with heart failure and preserved ejection fraction.
LBCT Recent HF Hospitalization in DELIVER | ESC Congress 2022
Jonathan W. Cunningham, MD, MPH, talks about dapagliflozin in hospitalized or recently hospitalized heart failure patients with mildly reduced and preserved ejection fraction.
-
-
Clinical Risk Score to Predict Pathogenic Genotypes in Patients with Dilated Cardiomyopathy
Valentin FusterSeptember 12, 2022 -
Sacubitril/Valsartan and Frailty in Patients with Heart Failure and Preserved Ejection Fraction
Valentin FusterSeptember 12, 2022 -
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients with Diabetes
Valentin FusterSeptember 12, 2022 -
Clinical Predictors of Recurrent Supraventricular Tachycardia in Infancy
Valentin FusterSeptember 12, 2022
Heart Failure With Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar 2/4
JACC Focus Seminar: Exercise, Cardiovascular Disease, and the Athlete's Heart
Topic Collections
- Basic & Translational Research
- Cardiometabolic
- Cardio-oncology
- Cerebrovascular Disease & Stroke
- Congenital Heart Disease
- Coronary, Peripheral & Structural Interventions